Table 4.
Comparison of platinum group vs. non – platinum group
| Characteristics | Platinum Group (%) | Non-Platinum Group (%) | P value |
| Total Number | 177 | 66 | |
| Median age, years (range) | 58 (range 26–81) | 64 (range 29–80) | 0.003 |
| Sex | 0.247 | ||
| Male | 112 (63.3) | 47 (71.2) | |
| Female | 65 (36.7) | 19 (28.8) | |
| ECOG performance status at baseline | 0.047 | ||
| 0 – 1 | 161 (91.0) | 54 (81.8) | |
| ≥ 2 | 16 (9.0) | 12 (18.2) | |
| Disease | 0.361 | ||
| Intrahepatic cholangiocarcinoma | 72 (40.7) | 20 (30.3) | |
| Gallbladder cancer | 51 (28.8) | 20 (30.3) | |
| Extrahepatic bile duct cancer | 38 (21.5) | 22 (22.2) | |
| Ampulla of Vater carcinoma | 16 (9.0) | 5 (7.6) | |
| Relapsed disease | 62 (35.0) | 22 (33.3) | 0.805 |
| Biliary stent or bypass during treatment | 46 (26.0) | 18 (27.3) | 0.84 |
| Disease associated infection during treatment (cholangitis, liver abscess) | 43 (24.3) | 19 (28.8) | 0.475 |
| Duration from off chemotherapy to death | 3.3 months (95% CI, 2.6–3.9) | 4.0 months (95% CI, 2.6–5.5) | 0.071 |
ECOG, Eastern Cooperative Oncology Group; CI, confidence interval